Pacer Advisors Inc. lifted its holdings in C.R. Bard, Inc. (NYSE:BCR) by 8.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,515 shares of the medical instruments supplier’s stock after buying an additional 116 shares during the period. Pacer Advisors Inc.’s holdings in C.R. Bard were worth $479,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of BCR. BlackRock Inc. lifted its position in shares of C.R. Bard by 1,365.7% in the first quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock worth $1,838,719,000 after buying an additional 6,893,346 shares during the last quarter. MARSHALL WACE ASIA Ltd acquired a new stake in shares of C.R. Bard in the first quarter worth about $132,062,000. Marshall Wace North America L.P. acquired a new stake in shares of C.R. Bard in the first quarter worth about $132,062,000. Renaissance Technologies LLC increased its stake in shares of C.R. Bard by 87.8% in the first quarter. Renaissance Technologies LLC now owns 956,700 shares of the medical instruments supplier’s stock worth $237,778,000 after purchasing an additional 447,300 shares during the period. Finally, Alliancebernstein L.P. increased its stake in shares of C.R. Bard by 267.0% in the first quarter. Alliancebernstein L.P. now owns 491,184 shares of the medical instruments supplier’s stock worth $122,079,000 after purchasing an additional 357,355 shares during the period. 79.34% of the stock is owned by institutional investors and hedge funds.
C.R. Bard, Inc. (NYSE BCR) opened at 320.38 on Friday. The firm has a market capitalization of $23.28 billion, a P/E ratio of 42.06 and a beta of 0.60. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $324.58. The stock has a 50 day moving average price of $320.21 and a 200 day moving average price of $296.89.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same quarter in the previous year, the firm earned $2.54 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.
A number of research firms have recently commented on BCR. BidaskClub upgraded C.R. Bard from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 8th. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a research note on Tuesday, June 6th. Jefferies Group LLC reiterated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research note on Thursday. Finally, BMO Capital Markets restated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research note on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. C.R. Bard currently has an average rating of “Hold” and an average target price of $285.67.
In other news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total value of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.80% of the stock is currently owned by insiders.
C.R. Bard Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with our FREE daily email newsletter.